Navigation Links
Mayo Clinic launches whole genome breast cancer study
Date:4/9/2012

ROCHESTER, Minn. -- The Breast Cancer Genome Guided Therapy Study (BEAUTY Project) will help physicians tailor chemotherapy to breast cancer patients based on their individual genomes and the genomes of their tumors. Mayo Clinic researchers will obtain three whole genome sequences: one from the patients' healthy cells before treatment, and two tumor genomes one before chemotherapy and one after. Patients will be paired with mouse "avatars" that will help physicians identify the best treatment for each person.

VIDEO ALERT: Audio and video resources are available on the Mayo Clinic News Blog(http://newsblog.mayoclinic.org/2012/04/05/mayo-clinic-launches-whole-genome-breast-cancer-study/).

"What is so exciting about this study is that it has the potential to really bring individualized medicine to our patients," says Matthew Goetz, M.D., Mayo oncologist and study co-leader. "It will transform how we conduct breast cancer research and how drug therapies are delivered to women with breast cancer."

In phase one of the BEAUTY Project, researchers will study the first 200 participants to look for common mutations that allow some tumors to adapt and thrive during chemotherapy. This information will help doctors identify new drugs and treatment strategies.

Women diagnosed with "high-risk" cancers who are scheduled to receive standard chemotherapy before surgery will have their healthy genome and their breast cancer tumor cells sequenced before treatment, and then receive the commonly prescribed chemotherapy to shrink the tumor. At surgery, the residual cancer tumor cells will be sequenced again to evaluate how they have mutated and adapted to chemotherapy.

In addition, patients' tumor tissue will be kept alive by implanting cell lines in immune-compromised mice -- before and after chemotherapy. The use of these mouse "avatars'' will let researchers study the effects of chemotherapy on individual patient tumors and identify the best treatment, without risk of harm to the patient.

"Patients are pleased after definitive breast surgery to be cancer free," says Judy Boughey, M.D., a Mayo breast surgeon and study co-leader. "Unfortunately, a subset of high-risk patients still may experience recurrence, even months or years later. We designed this study to give those patients hope that our ability to decode the genome of every patient might give us new tools to treat cancer."

Oncologists, surgeons, radiologists, and genomics and cancer researchers will work together to uncover the clues to effective individualized therapies and drug discovery. The BEAUTY Project is being funded by benefactors and the Mayo Clinic Center for Individualized Medicine, in collaboration with the Mayo Clinic Cancer Center.

"We are living in an era that I never thought I'd see during my career -- when we can sequence, in real time, the entire genome of a patient and her tumor and use that information to tailor treatment to the individual patient," says Richard Weinshilboum, M.D., director of the Pharmacogenomics Program in the Mayo Clinic Center for Individualized Medicine.

Together, the whole-genome sequencing data and transplanted cell lines are used to identify the gene pathways that influence individual patients' responses to chemotherapy. Armed with this deeper understanding of the genomics of cancer, doctors will be able to optimize treatment plans for individual patients.

This approach, called pharmacogenomics, is part of an ongoing effort at Mayo Clinic to personalize medicine for every patient and will help doctors prescribe the right drug for the right patient at the right dose and time. Additional work is being done in the Center for Individualized Medicine to develop clinical decision support tools to help doctors prescribe the best medication for each patient based on the latest pharmacogenomic knowledge.

Though initially being applied to breast cancer, this approach will be used in the future to study the treatment of many other types of cancer.


'/>"/>
Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Clinical news alert from the American Academy of Orthopaedic Surgeons
2. Clinical insight improves treatment with new lung cancer drug
3. First targeted nanomedicine to enter human clinical studies
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Early clinical data show galeterone safe, effective against prostate cancer
6. Cleveland Clinic study shows bariatric surgery improves, reverses diabetes
7. Stephanie R. Wilson, MD, to be presented with the Joseph H. Holmes Clinical Pioneer Award
8. Mayo Clinic researchers building melanoma vaccine to combat skin cancer
9. Mayo Clinic review: Blood pressure drug effective for treating PTSD-related nightmares
10. Standardized outcome measures proposed for asthma clinical research
11. Mayo Clinic: Robotic surgery proves successful, less invasive way to treat HPV-related oral cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... ... medical office in Petaluma, located at 167 Lynch Creek Way. The Petaluma office ... SRO sports medicine and rehabilitation services and on-site x-ray services. Two multi-specialist ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and ... longer use or need, from clothes to couches to dressers and bicycles. Roadie — ... them to the nearest Goodwill donation center through February 28th. , “January is ...
(Date:1/20/2017)... ... ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality nutritional supplements ... Trade Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures its entire ... to all clients at reasonable prices. At the ECRM trade show, it had a ...
(Date:1/20/2017)... ... , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in ... has been life-saving as she has been on the trial for more than ... with ovarian cancer in 2009. She underwent standard chemotherapy but a year later went ...
(Date:1/20/2017)... ... 2017 , ... “The Angel”: a heartwarming and earnest tale of faith ... his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former ... impassioned writer. , When asked of her new book, Marjorie says, “‘The Angel’ was ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 ARMO BioSciences, Inc., ... data on the Company,s lead investigational immuno-oncology drug AM0010 ... by the American Society of Clinical Oncology (ASCO), taking ... CA. "AM0010 induces the ... + T cells in the blood and tumors ...
(Date:1/20/2017)... Research and Markets has announced the ... HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, ... 2013 - 2024" report to their offering. ... The global clinical laboratory testing ... Introduction of innovative solutions on the grounds of maximum efficiency ...
(Date:1/20/2017)... -- Research and Markets has announced the addition ... Future" report to their offering. ... This research service on the global pharmaceutical ... provides a snapshot of the key participants in the market. ... from 2016 to 2020. The market is expected to grow at ...
Breaking Medicine Technology: